Turning Data Into Confidence: A New Era of Precision in Breast Cancer Care

The test is now ordered by breast surgeons or radiation oncologists in more than 85% of the top 50 U.S. cancer centers.
Medscape

Should We Still Call It Cancer? The Weight of a Word

Some experts believe the cancer label can be inappropriate for certain low-risk conditions and advocate dropping the C-word.
Cancer Therapy Advisor

Tumor Bed Boost Radiation After Post-Op Whole Breast Irradiation Reduces DCIS Recurrence

In non-low-risk DCIS of the breast, the addition of a TBB of radiation following postoperative WBI is associated with reduced local recurrence.
The American Journal of Managed Care

Smart Pill Bottles Offer Novel Solution to Adherence Crisis in Breast Cancer Care: Steven Manobianco, MD

Innovative smart pill bottles significantly enhance adherence to oral adjuvant endocrine therapy in early-stage breast cancer ...
Le Lézard

PreludeDx Announces First Independent Validation of AidaBreasttm, the Only Multi-Omic Test to Predict Locoregional Recurrence Risk and Radiation Therapy Benefit in Early-Stage ...

Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, today announced results from the first independent validation of AidaBreasttm, a novel multi-omic ...